✦ LIBER ✦

A factor X-TFPI hybrid protein inhibits B16 melanoma metastatic growth in mice

✍ Scribed by Thomas J. Girard

Book ID: 116913669
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 92 KB
Volume: 121
Category: Article
ISSN: 0049-3848
DOI: 10.1016/j.thromres.2007.04.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factor(s) from nonmacrophage bone marrow

Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice

✍ Maestroni, G. J. M.; Hertens, E.; Galli, P. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 228 KB

Inhibition of B16 melanoma growth and me

Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line

✍ Kenta Yoshiura, Toshihide Nishishita… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 424 KB

Transforming Growth Factor- 1 Inhibits B

Transforming Growth Factor- 1 Inhibits Basal Melanogenesis in B16/F10 Mouse Melanoma Cells by Increasing the Rate of Degradation of Tyrosinase and Tyrosinase-related Protein-1

✍ Martinez-Esparza, M.; Jimenez-Cervantes, C.; Beermann, F.; Aparicio, P.; Lozano, 📂 Article 📅 1997 🏛 The American Society for Biochemistry and Molecula 🌐 English ⚖ 794 KB

In vivo inhibition of tumor growth of B1

In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1β I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1β proteins

✍ PEZZELLA, K 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 649 KB

PTK787/ZK222584, a tyrosine kinase inhib

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

✍ Markus Rudin; Paul M. J. McSheehy; Peter R. Allegrini; Martin Rausch; Diana Baum 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

## Abstract Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non‐invasive measurement of tumour perfusion and blood vessel permeability assessed as the transfer constant, __K__^trans^, can be provided by dynamic contrast‐enha